Latest Breaking News On - Heijden research group - Page 1 : comparemela.com

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.

United statesPadcev keytrudaMichiels vanMichiel van der heijden research groupNetherlands cancer instituteDrug administrationCancers symposiumDer heijdenMichiel vanHeijden research groupNorth americaBladder cancerGenitourinary cancers symposium